Cochrane | Trusted evidence. Informed decisions. Better health.
WEBCochrane Hong Kong: Advancing evidence-based healthcare in Asia. 19 July 2024. News. World Evidence-Based Healthcare Day: Cochrane and global evidence leaders unite for world health and beyond. 17 July 2024. News. Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health.
Duloxetine for treating painful neuropathy, chronic pain or
WEBThe usual dose of duloxetine is 60 mg. At this dose, there was moderate quality evidence that duloxetine reduced pain in both painful diabetic peripheral neuropathy and fibromyalgia. In diabetic peripheral neuropathic pain, a 50% or better improvement with duloxetine 60 mg per day was just over one and a half times more likely than with placebo.
Oral painkillers available without prescription for acute pain
WEBNon-prescription (over-the-counter, or OTC) analgesics (painkillers) are used frequently. They are available in various brands, package sizes, formulations, and dose. They can be used for a range of different types of pain, but this overview reports on how well they work for acute pain (pain of short duration, usually with rapid onset).
How accurate are rapid antigen tests for diagnosing COVID-19?
WEBAccurate rapid diagnostic tests for SARS-CoV-2 infection would be a useful tool to help manage the COVID-19 pandemic. Testing strategies that use rapid antigen tests to detect current infection have the potential to increase access to testing, speed detection of infection, and inform clinical and public health management decisions …
Cochrane review of COVID-19 vaccines shows they are effective
WEBDec 7, 2022 · Most trials were no longer than two months in length. The review found that the following vaccines reduced or probably reduced the risk of COVID-19 infection compared to placebo: Pfizer/BioNTech, Moderna, CureVac COVID-19, Oxford-AstraZeneca, Janssen, Sputnik V (Gam-COVID-Vac), Sinopharm (WIBP CorV and BBIBP-CorV), Bharat (Covaxin), Novavax and ...
Which anticholinergic drug for overactive bladder symptoms
WEBThe review found that there are several anticholinergic drugs prescribed for adults with overactive bladder symptoms. The two most studied drugs are oxybutynin and tolterodine. These two drugs have similar effects but, on average, those taking oxybutynin were more likely to withdraw from the studies because of adverse effects, mainly dry mouth.
How accurate are the Addenbrooke's Cognitive Examination III
WEBThere is insufficient information in terms of both quality and quantity to recommend the use of either the ACE-III or mini-ACE for the screening of dementia or MCI in patients presenting with, or at high risk of, cognitive decline.
Are antibiotics an effective treatment for COVID-19 and do
WEBOct 22, 2021 · We are certain that risk of death in hospitalised COVID-19 patients is not reduced by treatment with azithromycin after 28 days. Further, based on moderate-certainty evidence, patients in the inpatient setting with moderate and severe disease probably do not benefit from azithromycin used as potential antiviral and anti-inflammatory treatment for COVID-19 regarding clinical worsening or ...
Strategies for managing sexual dysfunction caused by ... - Cochrane
WEBA wide range of management strategies are possible to address this problem, including behavioural, psychological and pharmacological approaches. 1. To determine the effectiveness of management strategies for sexual dysfunction caused by antidepressants. 2. To determine the adverse effects and acceptability of …
Which long-acting inhalers are the most effective and safest
WEBLong-acting bronchodilators such as long-acting β-agonist (LABA), long-acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations have been used in people with moderate to severe chronic obstructive pulmonary disease (COPD) to control symptoms such as dyspnoea and cough, and prevent exacerbations.
Skip to content